Skinvisible Adds Additional Patent Protection to Its Topical Drug Delivery Technology
26 Junio 2013 - 8:05AM
Marketwired
Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) today announced
that it has expanded its US patent protection for Invisicare®, its
unique topical drug delivery technology. Skinvisible has been
granted US Patent Number 8,481,058 for the topical composition
precursor for Invisicare with an expiry date of June 28, 2021. The
patent issued by the United States Patent and Trademark Office
(USPTO) is a division of Skinvisible's US patent "Topical
Composition, Topical Composition Precursor, and Methods for
Manufacturing and Using." This new patent expands Skinvisible's
patent portfolio to fourteen US and international patents and is
one of a series of five patents (including Skinvisible's initial
product patent) granted in the United States specifically
protecting Invisicare and the products formulated with it.
This latest patent granted to Skinvisible further protects the
composition of Invisicare; specifically the composition of the
precursor; the chemical composition that gives rise to the final
Invisicare delivery technology. Invisicare controls how ingredients
react on, in and through the skin. It binds products to the skin
resisting wash-off and rub-off along with controlling the release
of active ingredients and decreasing skin irritation. Invisicare
also has the ability to stabilize highly unstable active
ingredients and has previously announced patents granted for this
claim (avobenzone photostable for eight hours and retinoic acid in
acne treatments). Invisicare has been used to develop an infinite
array of prescription, over-the-counter and cosmeceutical skin care
products. Skinvisible's product pipeline includes formulations used
to treat skin conditions such as acne, actinic keratosis, fungal
infections, hemorrhoids, as well as products such as anti-aging
creams, scar lotions, hand sanitizers, callus removers, sunscreens,
sunless tanners, topical analgesics, skin protectants and
moisturizers. Skinvisible licenses out these products on an
exclusive basis to pharmaceutical, consumer goods and cosmetic
companies globally.
"We are confident that the granting of this new patent will
strengthen the patent position for our Invisicare technology which
provides our products with long-term market protection," said Terry
Howlett, President and CEO. "As we continue to aggressively
pursuing additional licensing opportunities for our products, we
also continue to expand our patent portfolio and pipeline of
products."
The comprehensive protection that the Invisicare patents cover
includes the composition of Invisicare, how it is manufactured and
its uses. Skinvisible's intellectual property portfolio includes:
U.S.(4), Canada, Europe(4), Australia, India, China, Hong Kong and
S. Korea along with three product specific US patents covering its
dermal barrier products, sunscreen formulations and retinoids. As
the demand for patented topical products grows, Skinvisible
continues its focus on expanding its global patent portfolio as
well as adding to its pipeline of prescription, over-the-counter
and cosmeceutical formulations available for exclusive
licensing.
About Skinvisible Pharmaceuticals, Inc Skinvisible
Pharmaceuticals is a research-and-development company that licenses
its proprietary formulations made with Invisicare, its patented
polymer delivery system that offers life-cycle management and
unique enhancements for topically delivered products. Invisicare
holds active ingredients on the skin for extended periods of time
resisting both wash off and perspiration along with controlling the
release of actives and reducing skin irritation. Skinvisible
receives a combination of license fees, and ongoing royalties for
its licensed product formulations. Skinvisible's value also lies in
its ability to continually generate new IP on topical products
formulated with Invisicare. www.skinvisible.com and
www.invisicare.com.
Forward-Looking Statements: This press release contains 'forward
looking' statements within the meaning of Section 21A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and are subject to the
safe harbors created thereby. Such statements involve certain risks
and uncertainties associated with an emerging company. Actual
results could differ materially from those projected in the forward
looking statements as a result of risk factors discussed in
Skinvisible, Inc. reports on file with the U.S. Securities and
Exchange Commission (including, but not limited to, a report on
Form 10Q for the year ending March 30, 2013).
Corporate Contact: Doreen McMorran Skinvisible
Pharmaceuticals, Inc. Phone: 702-433-7154 Email:
info@skinvisible.com
Skinvisible (QB) (USOTC:SKVI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Skinvisible (QB) (USOTC:SKVI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024